No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
暂无分享,去创建一个
James R. Rogers | S. Schneeweiss | D. Solomon | S. Gale | Seoyoung C. Kim | K. Sarsour | M. Klearman
[1] James R. Rogers,et al. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.
[2] M. Boers,et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis , 2016, Rheumatology.
[3] A. Duhamel,et al. Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study , 2016, International journal of rheumatic diseases.
[4] N. Wong,et al. A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. , 2016, The American journal of cardiology.
[5] J. Singh,et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.
[6] I. McInnes,et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.
[7] D. Solomon,et al. Active-comparator design and new-user design in observational studies , 2015, Nature Reviews Rheumatology.
[8] R. Hansen,et al. Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study , 2014, The Journal of Rheumatology.
[9] B. Kissela,et al. Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims , 2014, Circulation. Cardiovascular quality and outcomes.
[10] Jeremy A Rassen,et al. Metrics for covariate balance in cohort studies of causal effects , 2014, Statistics in medicine.
[11] P. Emery,et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy , 2014, Annals of the rheumatic diseases.
[12] R. Leonhart,et al. Researcher allegiance in psychotherapy outcome research: an overview of reviews. , 2013, Clinical psychology review.
[13] Abhi Shelat,et al. One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.
[14] F. Cunningham,et al. US Government Claims Databases , 2012 .
[15] J. Gurwitz,et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.
[16] Sebastian Schneeweiss,et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.
[17] H. Leffers,et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry , 2011, Annals of the rheumatic diseases.
[18] Jeffrey N Katz,et al. Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.
[19] P. Austin,et al. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.
[20] M. Genovese,et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.
[21] Mohsen Sadatsafavi,et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.
[22] Jeffrey N Katz,et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study , 2008, Arthritis research & therapy.
[23] J. Smolen,et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.
[24] Ken Kleinman,et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[25] Sebastian Schneeweiss,et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.
[26] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[27] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[28] JoAnn E. Manson,et al. Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.
[29] Peter Cummings,et al. Matched-pair cohort methods in traffic crash research. , 2003, Accident; analysis and prevention.
[30] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[31] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[32] K. Rothman,et al. VASECTOMY AND NON-FATAL MYOCARDIAL INFARCTION , 1981, The Lancet.